News Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Equities

TKD

JP3463000004

Real-time BOERSE MUENCHEN Other stock markets 09:13:01 2024-06-24 EDT			5-day change	1st Jan Change
24.04 ^EUR	+1.86%		-3.59%	-8.85%

11:02am	Hutchmed China notes Takeda obtains EU approval for Fruzaqla	AN
10:45am	Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hutchmed China notes Takeda obtains EU approval for Fruzaqla	05:02am	AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	04:45am	MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	03:59am	MT
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	03:01am	BU
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	02:29am	MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	11:08pm	MT
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	06-22	BU
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	06-22	CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	06-21	MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	06-21	DJ
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	06-21	BU
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	06-21	CI
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	06-21	AQ
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	06-21	MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	06-21	RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	06-20	MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	06-20	CI
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	06-19	AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	06-18	AQ
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	06-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Equities

TKD

JP3463000004

Summary

Filters